CL-108: Phase III started

Charleston and Daiichi Sankyo began an open-label, U.S. Phase III trial to evaluate oral CL-108 every 4-6 hours as needed for 2 weeks in about 150 patients with pain due to osteoarthritis (OA) of the ...